Enzo Biochem, Inc. (NYSE:ENZ – Get Free Report) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 478,700 shares, a drop of 5.0% from the August 31st total of 504,000 shares. Currently, 1.3% of the shares of the company are short sold. Based on an average daily volume of 90,600 shares, the short-interest ratio is presently 5.3 days.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in shares of Enzo Biochem by 2.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after acquiring an additional 64,417 shares during the period. Wittenberg Investment Management Inc. acquired a new position in Enzo Biochem in the fourth quarter valued at about $95,000. Finally, XTX Topco Ltd grew its stake in Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after buying an additional 13,735 shares in the last quarter. Institutional investors own 36.90% of the company’s stock.
Enzo Biochem Trading Down 0.9 %
ENZ stock opened at $1.11 on Wednesday. The business’s fifty day moving average price is $1.12 and its two-hundred day moving average price is $1.13. Enzo Biochem has a fifty-two week low of $0.99 and a fifty-two week high of $1.50.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on Enzo Biochem
Enzo Biochem Company Profile
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Read More
- Five stocks we like better than Enzo Biochem
- There Are Different Types of Stock To Invest In
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Why Invest in 5G? How to Invest in 5G Stocks
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.